AUSTRALIA BIOTECH INVEST 2013

Investor Highlights:

- Established in 1975 as a contract drug development company, $10.2m revenues in 2012
- API, finished dose form and clinical capabilities
- Facilities, experience and regulatory packages have set the platform for a rapid move into generic oncology drug registrations

IDT AUSTRALIA LIMITED (IDT:ASX)

28 October 2013 – Melbourne

New Management Team: Driving Growth and Value

A. Organic business growth and a return to profitability through better sales and marketing, and efficiencies

B. Previously underleveraged off balance sheet assets: DMFs and generic oncology registrations

C. Transformational high value assets accelerated by IDT capabilities and skills: pro-drugs and super-generics

Japanese pharma opportunities via new shareholder I'rom

idt australia limited

innovation containment compliance

Melbourne Manufacturing Campus

12,000m^2 freehold site
$70m+ replacement value, $10m unimproved land value

1. Engineering
2. Warehouses/ inward goods
3. Cytotoxic labs
4. Dev. labs
5. Administration
6. Controlled store
7. Antibiotic API/FP
8. HPAPI + sterile
9. Utilities
10. Oral dose forms

idt australia limited

innovation containment compliance

Melbourne Site Virtual Tour

CMAX: Royal Adelaide Hospital

- 445 studies completed over 20yrs
- Australia's largest clinical trial unit
- More patients safely and successfully dosed than any other facility
- Access to healthy volunteers and clinical patients

idt australia limited

innovation containment compliance

30 Years Experience in Dangerous and Difficult to Manufacture Drugs



idt australia limited

innovation containment compliance

Amended New Drug Application (ANDA)

- Process for registering a generic drug in the US

CMC package

3 Stability Batches

(+ bioequivalence data for oral drugs)

ANDA

Simple Registration Process

Generic Oncology Portfolio

idt australia limited

innovation containment compliance

Moving up the Value Chain

- Case Study, Drug X:
  - IDT currently the dominant supplier of API into a large market, yet capturing a less than 1% as an API supplier
  - Registration and supply of Finished Dose Form could increase IDT's share of value chain to approximately 50%
- There are a number of these assets within IDT that have not been leveraged



idt australia limited

innovation containment compliance

Corporate Snapshot (as at 23Oct13)

Financials

	2012	2013
Rev	$9.9m	$10.6m
EBIT	($3.6)	($4.4)
Cash use	($1.4)	($2.2)
Debt	$1.95m	

1 year trading history

Register

- 75.56 m shares on issue
- 500,000 options (unlisted)
- Top 20 holders 61.5% (22Oct13)

5 year trading history



idt australia limited

innovation containment compliance

Summary

- $70M+ purpose-built drug manufacturing and development facility, ample capacity for growth
- Australia's largest and only private clinical trials unit
- Reliable base revenues from drug development, drug manufacture, clinical trials
- 30 year history has resulted in the ownership of multiple Drug Master Files, now being converted to IDT generic drug registrations
- Capability and skills to acquire and grow value of larger, higher value projects such as reformulations or super-generics such as pro-drugs

Paul D. R. MacLeman

idt australia limited

Managing Director
+61 3 9801-8888
info@idtaus.com.au